Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
doxorubicin nucleolar and coiled-body phosphoprotein 1 small molecule NA drugbank Epithelial ovarian cancer[MeSHID:C538090]
Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Bronchogenic Carcinoma[MeSHID:D002283]
Carcinoma[MeSHID:D002277]
Urinary Bladder[MeSHID:D001743]
Nephroblastoma[MeSHID:D009396]
lymph nodes[MeSHID:D008198]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Thyroid carcinoma[MeSHID:D013964]
Body tissue[MeSHID:D014024]
Regression - mental defense mechanism[MeSHID:D012043]
Lymphoma[MeSHID:D008223]
Stomach[MeSHID:D013270]
Osteosarcoma[MeSHID:D012516]
Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Malignant neoplasm of breast[MeSHID:D001943]
Neuroblastoma[MeSHID:D009447]
Carcinoma
Transitional Cell[MeSHID:D002295]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Liver carcinoma[MeSHID:D006528]		 NA approved,investigational unknown
doxorubicin tert messenger rna NA Successful target TTD Epithelial ovarian cancer[MeSHID:C538090]
Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Bronchogenic Carcinoma[MeSHID:D002283]
Carcinoma[MeSHID:D002277]
Urinary Bladder[MeSHID:D001743]
Nephroblastoma[MeSHID:D009396]
lymph nodes[MeSHID:D008198]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Thyroid carcinoma[MeSHID:D013964]
Body tissue[MeSHID:D014024]
Regression - mental defense mechanism[MeSHID:D012043]
Lymphoma[MeSHID:D008223]
Stomach[MeSHID:D013270]
Osteosarcoma[MeSHID:D012516]
Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Malignant neoplasm of breast[MeSHID:D001943]
Neuroblastoma[MeSHID:D009447]
Carcinoma
Transitional Cell[MeSHID:D002295]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Liver carcinoma[MeSHID:D006528]		 NA approved unknown
doxorubicin dna topoisomerase 2-alpha small molecule NA drugbank , DGIDB Epithelial ovarian cancer[MeSHID:C538090]
Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Bronchogenic Carcinoma[MeSHID:D002283]
Carcinoma[MeSHID:D002277]
Urinary Bladder[MeSHID:D001743]
Nephroblastoma[MeSHID:D009396]
lymph nodes[MeSHID:D008198]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Thyroid carcinoma[MeSHID:D013964]
Body tissue[MeSHID:D014024]
Regression - mental defense mechanism[MeSHID:D012043]
Lymphoma[MeSHID:D008223]
Stomach[MeSHID:D013270]
Osteosarcoma[MeSHID:D012516]
Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Malignant neoplasm of breast[MeSHID:D001943]
Neuroblastoma[MeSHID:D009447]
Carcinoma
Transitional Cell[MeSHID:D002295]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Liver carcinoma[MeSHID:D006528]		 0.13 approved,investigational inhibitor
doxorubicin dna small molecule NA drugbank Epithelial ovarian cancer[MeSHID:C538090]
Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Bronchogenic Carcinoma[MeSHID:D002283]
Carcinoma[MeSHID:D002277]
Urinary Bladder[MeSHID:D001743]
Nephroblastoma[MeSHID:D009396]
lymph nodes[MeSHID:D008198]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Thyroid carcinoma[MeSHID:D013964]
Body tissue[MeSHID:D014024]
Regression - mental defense mechanism[MeSHID:D012043]
Lymphoma[MeSHID:D008223]
Stomach[MeSHID:D013270]
Osteosarcoma[MeSHID:D012516]
Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198]
Malignant neoplasm of breast[MeSHID:D001943]
Neuroblastoma[MeSHID:D009447]
Carcinoma
Transitional Cell[MeSHID:D002295]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Liver carcinoma[MeSHID:D006528]		 NA approved,investigational intercalation
click here to return to the previous page